New hope pill tested for tough blood cancers
NCT ID NCT07424833
Summary
This is a first-in-human study testing a new oral medication called APG-3288 for people with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
Conditions
Explore the condition pages connected to this study.